Navigation Links
AstraZeneca Response to February 21, 2008 Ruling In Re: Alabama Medicaid Pharmaceutical AWP Litigation - cv2005-219 - Circuit Court of Montgomery, Alabama
Date:2/21/2008

WILMINGTON, Del., Feb. 21 /PRNewswire-FirstCall/ -- AstraZeneca believes this lawsuit is legally and factually unfounded and we intend to appeal to the Alabama Supreme Court, if the trial court does not reject the jury's verdict. The case was based on the misleading premise that the Alabama State Medicaid Agency did not understand the basics on how drug prices are established and reported.

We believe numerous errors occurred during the proceedings and that the verdict should not be upheld.

For example, the Court ruled that important information on the workings of the Alabama pharmacy system be withheld throughout the trial. The Court also permitted evidence of earlier, unrelated settlements and proceedings in clear violation of the rules of evidence. These and other reversible errors were compounded by negative public comments by the trial lawyers and state leaders prior to the jury selection process.

AstraZeneca has fully complied with the law, government guidelines and contracts that govern Medicaid pricing. We currently provide medicines to Medicaid programs at the lowest price that we offer to our best business clients, as federal law requires.

AstraZeneca and the State Medicaid program share a common goal of helping people access the medicines they need.

To help patients who have difficulty affording their medicines, we offer patient assistance programs side by side with our medicines. In the last two years alone, AstraZeneca helped more than 28,800 Alabama patients receive more than $25.5 million in savings through its prescription savings programs.


'/>"/>
SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
2. Epistem plc and AstraZeneca Complete Plucked Hair Biomarker Study for Oncology Drug Development
3. AstraZeneca and Banner Alzheimers Institute Collaborate to Evaluate New Tool Targeting Alzheimers Disease
4. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
5. Pediatric Asthma Programs Featuring PARI Pharmas eFlow Acquired by AstraZeneca
6. Solstice Neurosciences, Inc. Issues Corporate Response to FDA Early Communication
7. Statement by John Bailey, Chief Scientist: The Personal Care Products Council Response to Study on Phthalate Exposure in Baby Care Products
8. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
9. CNS Response, Inc Completes Neuro-Therapy Clinic Acquisition; Names Daniel A. Hoffman, MD Chief Medical Officer
10. Triage study challenges notions of emergency medical response to disaster
11. CNS Response, Inc. Announces Acquisition of Neuropsychiatric Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... 16, 2017   Biostage, Inc. (Nasdaq: ... company developing bioengineered organ implants to treat cancers and ... announced today the closing on February 15, 2017 of ... common stock and warrants to purchase 20,000,000 shares of ... The offering was priced at $0.40 per share of ...
(Date:2/16/2017)...  Dermata Therapeutics, LLC, a biotechnology company developing ... of dermatological diseases, today announced it has completed ... into a $5 million credit facility with Silicon ... capital for general corporate purposes to further Dermata,s ... of serious diseases treated by dermatologists.   ...
(Date:2/16/2017)...  Windtree Therapeutics, Inc. (Nasdaq: WINT ... KL4 surfactant therapies for respiratory diseases, announced today ... that aerosolized KL4 surfactant reduced lung inflammation and ... model. The Company believes that these preclinical data ... supports the role of KL4 surfactant as a ...
(Date:2/16/2017)... ... February 16, 2017 , ... ... industry leading Biochemistry Services specifically targeting the rapidly growing needs of the ... the biochemical and biosimilar characterization , product-related impurity characterization, aggregation ...
Breaking Biology Technology:
(Date:1/23/2017)... 2017  The latest mobile market research from Acuity ... dramatically. The quarterly average price of a biometric smartphone ... Q4 2016.  There are now 120 sub-$150 models on ... from just 28 a year ago at an average ... Maxine Most , Acuity Market Intelligence Principal, "Biometric Smartphones ...
(Date:1/18/2017)...  In vitro diagnostic (IVD) companies were very active ... and Kalorama Information expects that trend to continue – ... Generally, uncertainty in reimbursement and healthcare reform in ... the acquisitions landscape. Instead of looking to buy technology, ... outside of their home country and also to increase ...
(Date:1/12/2017)...  New research undertaken by Fit Small Business ... participants were simply asked which office technology had they not ... standard issue.  Insights on what will be key ... futurists and industry leaders including Penelope Trunk , ... Some of these findings included; ...
Breaking Biology News(10 mins):